Director Dealing

Director Dealing

Manchester, UK - 16 April 2019 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, announces it was notified on 15 April 2019, that Dr Cathy Prescott, a Non-Executive Director of the Company, acquired 56,1...

16th April, 2019 Read More

SkinBiotix® shows efficacy in first human study

SkinBiotix® shows efficacy in first human study

Manchester, UK - 8 April 2019 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, provides the results of its first human study....

8th April, 2019 Read More

CEO Designate Appointment

CEO Designate Appointment

Manchester, UK - 29 March 2019 - SkinBioTherapeutics plc (AIM: SBTX or the "Company"), a life sciences company focused on skin health, announces the appointment of Stuart Ashman as an Executive Director of the Company, subject to the completion of regulatory due diligence checks....

29th March, 2019 Read More

Issue of Equity and Related Party Transaction

Issue of Equity and Related Party Transaction

SkinBioTherapeutics plc (AIM: SBTX) ("SkinBioTherapeutics" or the "Company"), a life sciences company focused on skin health, announces that it has raised a total of £1,500,000 via a placing of 9,375,000 new ordinary shares ("Placing Shares") at a price of 16 penc...

18th February, 2019 Read More

Half year results

Half year results

Manchester, UK - 14 February 2019 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2018....

14th February, 2019 Read More

Interim update on human studies and extension of IP portfolio

Interim update on human studies and extension of IP portfolio

Manchester, UK - 31 January 2019 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, provides interim data on the third and final phase of its human studies and an update on one of its patents....

31st January, 2019 Read More
investors logo